| Literature DB >> 24826368 |
Sasha A Fleary1, Robert W Heffer1, E Lisako J McKyer2.
Abstract
This study explored the extent to which nonprescription and prescription drugs misuse among adolescents/young adults are related to their perception that it is safer than illicit drugs, ease of access, and lower societal stigma. Adolescents/young adults (N = 465; M age = 18.57, SD = 0.86) completed an online survey about their nonprescription and prescription drug misuse, other substance use, and correlates of use. Perceived risk, societal stigma, and access to nonprescription and prescription drugs were predictive of misuse. Results support program planners working towards targeting perceived risk and societal stigma in reducing misuse and the need to restrict and monitor access to nonprescription and prescription drugs for adolescents/young adults.Entities:
Year: 2013 PMID: 24826368 PMCID: PMC4007747 DOI: 10.1155/2013/709207
Source DB: PubMed Journal: J Addict ISSN: 2090-7850
Descriptive statistics for the sample.
| Users | Age of first use in years | Perceived risk | Perceived societal stigma, parent | Perceived societal stigma, peer | |
|---|---|---|---|---|---|
| Prescription drugs | |||||
| Prescription pain | 50 (10.7) | 17.32 (1.48) | 5.30 (1.71) | 4.38 (.90) | 3.93 (1.09) |
| Prescription sedatives | 22 (4.7) | 17.23 (1.66) | 5.84 (1.43) | 4.71 (.60) | 4.23 (.90) |
| Prescription stimulants | 41 (8.8) | 18.05 (2.30) | 5.06 (1.83) | 4.51 (.85) | 3.98 (1.09) |
| Nonprescription drugs | |||||
| Nonprescription pain | 61 (13.1) | 15.18 (2.84) | 3.60 (2.00) | 2.43 (1.21) | 3.19 (1.33) |
| Nonprescription | 22 (4.7) | 17.09 (1.60) | 4.82 (1.74) | 3.95 (1.12) | 3.77 (1.11) |
| No distinction | |||||
| Cough/cold syrup | 42 (9) | 15.33 (3.18) | 3.99 (2.00) | 2.70 (1.31) | 3.42 (1.31) |
| Illicit drugs | |||||
| Marijuana | 134 (29.9) | 17.78 (1.67) | 5.07 (1.90) | 4.87 (.48) | 3.49 (1.37) |
| Crack or cocaine | 10 (2.1) | 17.80 (1.55) | 6.76 (.71) | 4.97 (.30) | 4.73 (.58) |
Significant correlations and mean differences of perceived risk and perceived societal stigma (peer disapproval) of non-prescription and prescription drug misuse with illicit drug use.
| Perceived riska | Perceived societal stigma, peera | Perceived societal stigma, parenta | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marijuana | Crack or cocaine | Marijuana | Crack or cocaine | Marijuana | Crack or cocaine | |||||||
|
| MD |
| MD |
| MD |
| MD |
| MD |
| MD | |
| Prescription drugs | ||||||||||||
| Pain | .32 | .22* | .30 | −1.46 | .45 | .44 | .35 | −.80 | .14** | −.43 | .20 | −.59 |
| Sedatives and tranquilizers | .37 | .77 | .38 | −.92 | .44 | .74 | .43 | −.50 | .30 | −.10** | .41 | −.25 |
| Stimulants | .46 | −.01 (ns) | .27 | −1.69 | .50 | .48 | .34 | −.76 | .34 | −.30 | .31 | −.45 |
| Nonprescription Drugs | ||||||||||||
| Pain | .25 | −1.47 | .21 | −3.15 | .34 | −.30 | .17 | −1.54 | .12* | −2.38 | .07 (ns) | −2.53 |
| Sleeping pills | .31 | −.25* | .24 | −1.93 | .41 | .27 | .32 | −.97 | .18 | −.86 | .18 | −1.01 |
| No distinction | ||||||||||||
| Cough/cold syrup and pills | .49 | −1.09 | .23 | −2.77 | .36 | −.08 (ns) | .23 | −1.31 | .08 (ns) | −2.11 | .05 (ns) | −2.26 |
MD: mean difference; ns: nonsignificant.
a P ≤ 0.001 unless were indicated, *P < 0.05, **P < 0.01.
Results of binary logistic regression analyses predicting misuse from risk perception, societal stigma, and access.
| Prescription | Nonprescription | No Distinction | ||||
|---|---|---|---|---|---|---|
| Pain OR (95% CI) | Sedatives and Tranquilizers OR (95% CI) | Stimulants OR (95% CI) | Pain OR (95% CI) | Sleep OR (95% CI) | Cough/Cold OR (95% CI) | |
| Step 1 {Δ | (.06) | (.10) | (.08) | (.02) | (.03) | (.04) |
|
| ||||||
| Age | 1.06 (.75, 1.49) | 1.20 (.76, 1.88) | 1.73** (1.27, 2.36) | 1.03 (.75, 1.41) | .85 (.47, 1.54) | 1.21(.89, 1.66) |
| Gender | .68 (.37, 1.25) | .59 (.24, 1.44) | .94 (.48, 1.84) | .61 (.35, 1.06) | 1.65 (.63, 4.34) | .54 (.28, 1.04) |
| Ethnicitya | ||||||
| Black | .20** (.07, .56) | .16** (.04, .63) | .50 (.13, 1.88) | 2.54 (.33, 19.71) | .75 (.09, 6.02) | .00b |
| Asian | .00b | .00b | .00b | .95 (.05, 16.50) | .74 (.04, 12.95) | .00b |
| Hispanic | .19 (.03, 1.10) | .22 (.02, 2.37) | .18 (.02, 2.114) | 3.63 (.37, 36.83) | .00b | .00b |
| Other | .30 (.09, 1.03) | .67 (.15, 2.96) | .32 (.06, 1.66) | 2.67 (.31, 23.19) | 1.02 (.11, 9.92) | .00b |
|
| ||||||
| Step 2 {Δ | (.28) | (.31) | (.31) | (.30) | (.29) | (.27) |
|
| ||||||
| Age | 1.00 (.66, 1.51) | .90 (.45, 1.80) | 2.18*** (1.48, 3.21) | .94 (.65, 1.35) | .77 (.42, 1.40) | 1.28 (.89, 1.83) |
| Gender | .96 (.47, 1.99) | .49 (.15, 1.54) | 1.23 (.55, 2.72) | .67 (.35, 1.26) | 1.64 (.56, 4.80) | .52 (.25, 1.10) |
| Ethnicitya | ||||||
| Black | .23* (.07, .76) | .09** (.02, .54) | .66 (.13, 3.41) | 2.52 (.29, 21.93) | .38 (.04, 4.11) | .00b |
| Asian | .00b | .00b | .00b | .65 (.03, 13.66) | 1.53 (.06, 40.06) | .00b |
| Hispanic | .09* (.01, .72) | .18 (.01, 3.15) | .21 (.01, 3.41) | 3.35 (.28, 40.55) | .00b | .00b |
| Other | .29 (.07, 1.22) | .48 (.08, 3.07) | .85 (.12, 6.00) | .62 (.25, 1.51) | 1.21 (.09, 17.02) | .00b |
| PR | .78* (.64, .96) | .63** (.46, .87) | .71** (.56, .91) | .84 (.67, 1.04) | .91 (.69, 1.20) | 1.00 (.79, 1.27) |
| PSSD | 1.42 (.42, 4.89) | .28 (.07, 1.14) | .62 (.19, 2.02) | .62 (.25, 1.51) | .56 (.14, 2.28) | .65 (.23, 1.81) |
| PSS: | ||||||
| Parent | .92 (.63, 1.34) | 21.03* (1.9, 229.7) | .77 (.52, 1.15) | 1.08 (.77, 1.51) | .81 (.49, 1.34) | .93 (.64, 1.35) |
| Peer | .52*** (.36, .75) | .84 (.47, 1.50) | .56** (.36, .87) | .70 (.48, 1.02) | .69 (.39, 1.19) | .52** (.34, .79) |
| Peer use | 1.12 (.97, 1.32) | 1.50** (1.16, 1.94) | 1.15 (.98, 1.35) | 1.24*** (1.12, 1.36) | 1.14 (.89, 1.46) | 1.19** (1.06, 1.33) |
| Access | ||||||
| School | 2.09* (1.01, 4.35) | 1.87 (.60, 5.76) | 1.54 (.65, 3.63) | 1.26 (.64, 2.47) | 1.03 (.36, 2.90) | 1.55 (.73, 3.30) |
| Home | 1.69 (.84, 3.42) | 3.57 (.75, 16.90) | 1.14 (.36, 3.57) | .10 (.01, 1.27) | 16.5 (3.4, 79.1)*** | .00b |
PR: perceived risk; PSS: perceived societal stigma; PSSD: prescription safer than street drug; ΔR 2: change in Nagelkerke R 2 at each step; aWhite/Caucasian is the comparison group; bodds ratio cannot be computed due to extremely large standard error.
*P < 0.05, **P < 0.01, ***P ≤ 0.001.